Paratek Pharmaceuticals to acquire Optinose and its nasal drug-device Xhance for up to $330M, expanding beyond antibiotics ...

Optinose has received approval from the US Food and Drug Administration (FDA) for its XHANCE nasal spray to treat chronic rhinosinusitis without nasal polyps. Indicated for patients aged 18 years ...

YARDLEY, PA — The U.S. Food and Drug Administration (FDA) recently approved XHANCE® (fluticasone propionate) nasal spray, developed by Optinose (NASDAQ: OPTN), for the treatment of chronic ...

The active ingredient of Xhance is fluticasone propionate. It’s available as the generic drug fluticasone propionate nasal spray. A generic drug is considered to be as safe and effective as the ...

Xhance (fluticasone propionate) is a brand-name nasal spray that’s prescribed for chronic rhinosinusitis with or without nasal polyps in adults. Xhance has interactions with some other drugs ...